Effects of ipratropium bromide combined with budesonide on pulmonary function and airway remodeling factors in patients with asthma-COPD overlap syndrome
Objective To explore the effects of ipratropium bromide combined with budesonide on pulmonary function and airway remodeling factors in patients with asthma-COPD overlap syndrome(ACOS).Methods A total of 84 patients with ACOS who received treatment in Baoji Third Hospital from December 2021 to December 2023 were selected as the study objects,and were divided into a control group and an observation group with 42 patients in each group by the random number table method.In the control group,there were 24 males and 18 females,aged(53.42±6.35)years,with a course of disease of(4.18±0.75)years;budesonide inhalation therapy was administered with budesonide suspension(2 ml)mixed with normal saline(4 ml),twice a day.In the observation group,there were 22 males and 20 females,aged(53.36±6.12)years,with a course of disease of(4.13±0.66)years;the patients were treated with budesonide combined with ipratropium bromide,budesonide aerosol inhalation was the same as the control group,and ipratropium bromide aerosol inhalation was administered twice a day,2 presses per time.Both groups were treated continuously for 3 months.The levels of inflammatory factors,endothelial cell function indicators[nitric oxide(NO),endothelin-1(ET-1),and soluble intercellular adhesion molecule-1(sICAM-1)],airway remodeling factors,lung function[forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),and maximum voluntary ventilation(MW)]were compared between the two groups before and after 3 months of treatment,and the disease symptoms were assessed by the Chronic Obstructive Pulmonary Disease Assessment Test(CAT)and Asthma Control Test(ACT)in both groups.x2 test and t test were used.Results Three months after treatment,the levels of IL-6,TNF-α,hs-CRP,ET-1,and sICAM-1 in the observation group were(13.82±2.44)pg/L,(14.39±2.61)pg/L,(3.22±0.50)mg/L,(2.41±0.27)ng/L,and(412.25±50.26)g/L,and those in the control group were(21.75±3.96)pg/L,(23.14±3.42)pg/L,(5.14±0.78)mg/L,(2.85±0.31)ng/L,and(523.34±59.14)g/L,with statistically significant differences(all P＜0.05).The levels of airway remodeling factors in the observation group were lower than those in the control group(all P＜0.05).The levels of NO,FEV1,FVC,and MW in the observation group were higher than those in the control group[(66.34±7.03)μmol/L vs.(58.23±6.27)μmol/L,(2.37±0.23)L vs.(2.12±0.21)L,(2.66±0.28)L vs.(2.41±0.21)L,(82.10±6.42)L/min vs.(73.88±6.08)L/min],with statistically significant differences(all P＜0.05).The CAT and ACT scores of the observation group were(23.01±2.72)points and(16.12±2.65)points,and those of the control group were(16.36±2.51)points and(22.97±3.41)points,with statistically significant differences(t=1 1.644,10.279,both P＜0.05).Conclusion Ipratropium bromide combined with budesonide aerosol inhalation can reduce the levels of airway remodeling factors and improve the lung function in ACOS patients.
万方数据
维普
